Post hoc ATTAIN data put weight loss at about 13% to 14% on the 36 mg dose whether women were pre, peri or postmenopausal. The results haven't been peer reviewed yet.
Recap by typeshit. Full story at Medical News Today.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
Josh Holyfield argues that appetite suppression isn't the most important effect of retatrutide for anyone trying to change body composition. These are his views, not trial findings.
Dr Kazarian points out that retatrutide hasn't been approved yet, so he says anyone using it now isn't getting the genuine drug from Lilly.
Loading…